GeminIQ Website Logo

Viewing CURX free

Subscribe for full history, 90+ metrics, screener, watchlist...

Curanex Pharmaceuticals Inc

CURX

Subscribe to unlock 17+ years of data

Financial Statements

Values in Millions ($)
2026-06-30
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Financial statements beyond 3 years are for subscribers only.

Unlock 17+ years of income statements, balance sheets, and cash flow statements

Start 7-day free trial
Subscriber-only column
Assets
Assets Current
Cash
34560
Prepaid Expense Current
24690
Other Assets Current
----1
Assets Current
5811141
Operating Lease Right Of Use Asset
00000
Assets
5812141
Liabilities And Stockhold…
Liabilities Current
Accrued Liabilities Current
00000
Accounts Payable Current
00000
Interest Payable Current
----0
Operating Lease Liability Current
00000
Liabilities Current
00000
Operating Lease Liability Noncurrent
000-0
Long Term Loans Payable
----0
Liabilities
00000
Stockholders Equity
Common Stock Value
00000
Preferred Stock Value
00000
Additional Paid In Capital Common Stock
161616161
Retained Earnings Accumulated Deficit
-11-8-5-2-1
Stockholders Equity
5811140
Liabilities And Stockholders Equity
5812141
Common Stock Shares Authorized
475475475475475
Common Stock Par Or Stated Value Per Share
00000
Common Stock Shares Issued
2828282824
Shares Outstanding
2828282824
Preferred Stock Shares Authorized
2525252525
Preferred Stock Par Or Stated Value Per Share
00000
Preferred Stock Shares Issued
11111
Preferred Stock Shares Outstanding
11111

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Custom Table

0/5
Search a metric to start building a table

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Interactive Financial Visualizations

0/1
Search a metric to start building a visual

Subscribe to unlock 17+ years of data

Earnings Market Reaction

Fiscal Year
Q1 1 Month
Q1 2 Month
Q1 3 Month
Q2 1 Month
Q2 2 Month
Q2 3 Month
Q3 1 Month
Q3 2 Month
Q3 3 Month
Q4 1 Month
Q4 2 Month
Q4 3 Month
2026-3.19%-18.53%-38.98%---------
2025----90.15%-91.44%-93.85%-12.52%-27.75%-46.82%-10.45%-31.97%-42.62%

Earnings Market Reaction data beyond 3 years is for subscribers only.

Unlock the full earnings market reaction history

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics
2026-06-30
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Metric history beyond 3 years is for subscribers only.

Unlock 17+ years of history across 90+ calculated metrics

Start 7-day free trial
Subscriber-only column
Liquidity Ratios
Current Ratio
45.95
62.87
81.93
77.53
9.37
Quick Ratio
28.17
31.22
36.29
31.35
9.29
Working Capital
4.69M
7.96M
11.09M
14.23M
635.41K
Leverage & Debt
Debt to Equity
0.06
0.04
0.03
0.01
1.58
Interest Coverage TTM
-1,962.97
-750.27
-
-
-
Debt Ratio
0.06
0.04
0.03
0.01
0.61
Efficiency & Turnover
Asset Turnover TTM
0.00
0.00
-
-
-
Per Share Metrics
Diluted EPS TTM
-0.37
-0.26
-
-
-
Free Cash Flow Per Share TTM
-0.41
-0.40
-
-
-
Dividend Per Share TTM
0.00
0.00
-
-
-
Valuation Metrics
P/E TTM
-0.71
-1.96
-
-
-
P/B TTM
1.57
1.79
0.75
1.29
-
Market Cap
7.52M
14.48M
8.44M
18.43M
-
Enterprise Value
4.58M
10.47M
3.47M
12.60M
-
Calculated Values
Free Cash Flow TTM
-11.56M
-11.44M
-
-
-
Net Debt
-2.94M
-4.02M
-4.97M
-5.83M
-108.86K
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of data

No insider data available.

Subscribe to unlock 17+ years of data

Institutional Ownership

No data available for chart
2026-03-31
1.16%
Inst. Shares: 327,761
Shares Outstanding: 28,344,545
2025-12-31
1.62%
Inst. Shares: 412,763
Shares Outstanding: 25,497,328
2025-09-30
1.12%
Inst. Shares: 286,093
Shares Outstanding: 25,599,673

Curanex Pharmaceuticals Inc (CURX) — SEC Financial Statements & Analysis

Curanex Pharmaceuticals Inc (CURX) is a pharmaceutical preparations company, incorporated in NV. Curanex Pharmaceuticals Inc trades on Nasdaq as: CURX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Curanex Pharmaceuticals Inc reported a Debt-to-Equity ratio of 0.06x, a Price-to-Book (P/B) ratio of 1.57x (TTM), at a market cap of $7.52M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity
0.06x
P/B TTM
1.57x
Market Cap
$7.52M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Curanex Pharmaceuticals Inc in?

Curanex Pharmaceuticals Inc (CURX) operates in the Pharmaceutical Preparations industry.

What is CURX's market cap?

Curanex Pharmaceuticals Inc (CURX) has a market capitalization of $7.52M as of 2026-06-30.

What exchange does CURX trade on?

Curanex Pharmaceuticals Inc (CURX) trades on the Nasdaq.

Where is Curanex Pharmaceuticals Inc incorporated?

Curanex Pharmaceuticals Inc is incorporated in NV.

Wall Street's data.
Main Street's price.